Volume 1, Issue 4, Pages 314-321 (July 2017) Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age- Related Macular Degeneration  Charles C. Wykoff, MD, PhD, William C. Ou, BS, David M. Brown, MD, Daniel E. Croft, BA, Rui Wang, BA, John F. Payne, MD, W. Lloyd Clark, MD, Nizar Saleh Abdelfattah, MD, SriniVas R. Sadda, MD  Ophthalmology Retina   Volume 1, Issue 4, Pages 314-321 (July 2017) DOI: 10.1016/j.oret.2016.12.004 Copyright © 2016 American Academy of Ophthalmology Terms and Conditions

Figure 1 Graphs showing (A) mean and (B) mean change from baseline in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters) in monthly and treat-and-extend (TREX) cohorts through 24 months. Ophthalmology Retina  2017 1, 314-321DOI: (10.1016/j.oret.2016.12.004) Copyright © 2016 American Academy of Ophthalmology Terms and Conditions

Figure 2 Bar graph showing distribution of maximum extension intervals and outcomes from rechallenge within the treat-and-extend (TREX) cohort. Persistent Wet = patients who had a wet macula at every study visit; Stable Dry = patients who remained dry after achieving a dry macula; Static Maximum Interval = patients who were unable to be extended substantially beyond their initial maximum extension interval. Successful Re-challenge = patients who were able to maintain a dry macula at an interval more than 2 weeks longer than their initial maximum extension interval. Ophthalmology Retina  2017 1, 314-321DOI: (10.1016/j.oret.2016.12.004) Copyright © 2016 American Academy of Ophthalmology Terms and Conditions